Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587221 | 0.76 | MIF (0.42) | CYP2C19SMN1; SMN2HPGDALDH1A1KDM4E | |
| SCHEMBL488830 | 0.76 | CYP2C19 (0.39) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL4957513 | 0.74 | TSHR (0.46) | TSHRHTR2ATAAR1ATMHRH1 | |
| Benzene SCHEMBL28136546 | 0.69 | TSHR (0.50) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL109223 | 0.69 | TSHR (0.50) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL2923052 | 0.68 | CYP2C19 (0.52) | TSHRCYP2C19SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL30724553 | 0.67 | TSHR (0.48) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL11666238 | 0.67 | TSHR (0.48) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9691228 | 0.67 | TSHR (0.48) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 | |
| Ethylene SCHEMBL27607233 | 0.67 | TSHR (0.48) | TSHRCYP2C19SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001041763-A1 | TREATMENT OF ADDICTION DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-06-14 | — | — | WO | claimed |
| US-20080089859-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | HOLMAN ANDREW | 2008-04-17 | — | — | US | disclosed |
| EP-1311251-A2 | USE OF DOPAMINE D2/D3 RECEPTOR AGONISTS TO TREAT FIBROMYALGIA | Holman, Andrew J. (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020165246-A1 | Administration of sleep restorative agents | HOLMAN ANDREW (US) | 2002-11-07 | — | — | US | disclosed |
| WO-2002069974-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | HOLMAN ANDREW (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002005797-A2 | USE OF DOPAMINE D2/D3 RECEPTOR AGONISTS TO TREAT FIBROMYALGIA | HOLMAN ANDREW J (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6300365-B1 | ADMINISTERING NON-ERGOT DOPAMINE D.SUB.2 /D.SUB.3 RECEPTOR AGONIST OR ACID ADDITION SALT COMPRISING 3(H)-INDOLONE COMPOUND FOR THERAPY OF FIBROMYALGIA | INMEDIX, LLC | 2001-10-09 | — | — | US | disclosed |
| US-6277875-B1 | FIBROMYALGIA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2001-08-21 | — | — | US | disclosed |
| WO-2001041763-A1 | TREATMENT OF ADDICTION DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-06-14 | — | — | WO | disclosed |
| US-4886812-A | REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA | DR. KARL THOMAE GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| US-4843086-A | HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1989-06-27 | — | — | US | disclosed |
| US-4731374-A | PARKINSON*S DISEASE | DR. KARL THOMAE GMBH (DE) | 1988-03-15 | — | — | US | disclosed |
| EP-0186087-A1 | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs | Dr. Karl Thomae GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165246-A1 | Administration of sleep restorative agents | GAP43, PER2, PSAP | TSHR 4696/4885CYP2C19 4104/4885SMN1; SMN2 247/4885 |
| US-20080089859-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | GAP43, PER2, PSAP | TSHR 4706/4885CYP2C19 4088/4885SMN1; SMN2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.